{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/asthma/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"d2031db2-44fd-55bb-b5c8-d085b387747a","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field eeaeb8c9-c497-4d17-a92a-ab0529701025 --><h2>Changes</h2><!-- end field eeaeb8c9-c497-4d17-a92a-ab0529701025 -->","summary":null,"htmlStringContent":"<!-- begin item a3f17739-8081-47cc-a71e-19a61fcc1b02 --><!-- begin field 3d213d55-9047-4c72-a58a-3f51620d1036 --><p><strong>October 2020 </strong>— minor update. A typographical error has been corrected.</p><p><strong>April 2020 </strong>— minor update. The topic has been updated to take into account the latest BTS guideline on macrolide use. </p><p><strong>April 2020 </strong>— minor update. Frequency of use of Alvesco inhaled corticosteroid pressurized metered dose inhaler has been updated.</p><p><strong>April 2020 </strong>— minor update. New management scenario created to provide information regarding COVID-19. </p><p><strong>February 2020 </strong>— minor update. Topic updated in line with NICE, 2020, <em>Asthma: diagnosis, monitoring and chronic asthma management </em>update.</p><p><strong>November 2019</strong> — minor update. Quality Standards updated.</p><p><strong>September 2019</strong> — minor update. The topic has been updated to take into account recommendations in the latest BTS/SIGN guideline. </p><p><strong>April 2018</strong> — minor update. Spiriva Respimat is now licensed as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year.</p><p><strong>March 2018</strong> — reviewed. A literature search was conducted in March 2018 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring. No major changes to the recommendations have been made.</p><!-- end field 3d213d55-9047-4c72-a58a-3f51620d1036 --><!-- end item a3f17739-8081-47cc-a71e-19a61fcc1b02 -->","topic":{"id":"d631356f-d3a3-51fb-807c-5517c470a5af","topicId":"2a0a90e6-1c4e-4b6a-9ce2-3379dd122594","topicName":"Asthma","slug":"asthma","lastRevised":"Last revised in October 2020","chapters":[{"id":"c7185669-75fd-5c6e-b105-63a3237634ac","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9fe1ab10-4b4d-5ba8-9ef0-00631cd00ea4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"770d55df-2c61-5d1e-83d9-92b12ccae96a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d2031db2-44fd-55bb-b5c8-d085b387747a","slug":"changes","fullItemName":"Changes"},{"id":"a993bde1-1ac8-529e-8a3e-201a8c082ab2","slug":"update","fullItemName":"Update"}]},{"id":"eae8fe92-3941-512e-bcc6-f1e15157c1ae","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8e125759-cd9d-510d-9659-3c2e77baa755","slug":"goals","fullItemName":"Goals"},{"id":"a6c91cd5-1ce2-5c60-86cc-341a9dccf3d4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a5746054-2f36-5a42-9e7c-7af9107ad99b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5fd19cd9-6ac7-54c8-89be-817d58e41309","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f7339086-c653-53dd-990c-6d470fa223b8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f43b79db-3c62-58ee-bb70-932e6613eea6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0d12a387-5436-5c75-92c0-189cb391ec7a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8fbe04ed-5fd7-54c9-be84-6c959f75af3b","slug":"definition","fullItemName":"Definition"},{"id":"5cbe6206-f80c-5a71-8e4d-a4d44e392874","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2fb588ab-6181-5aec-8a4a-fb368098329d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b786654f-5e6e-5e5f-9ead-abaca7f99ba5","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c0b65c0b-957e-538e-83e9-5b4af2d8e6dd","slug":"complications","fullItemName":"Complications"}]},{"id":"574c6193-f36f-5bf7-946a-d8c688476131","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"351773e5-286c-5560-8402-79c2d92d4aa6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"053272da-fea9-5df6-842a-0de682896aaf","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7b632c20-012f-590e-a01e-cda5715d6f14","fullItemName":"Management","slug":"management","subChapters":[{"id":"f95fb73f-b749-53a5-b857-4d2bb9945667","slug":"newly-diagnosed-asthma","fullItemName":"Scenario: Newly-diagnosed asthma"},{"id":"2878c5f8-3e3f-52c8-a9bd-7988906b6f99","slug":"follow-up","fullItemName":"Scenario: Follow-up"},{"id":"2458c073-8efb-5a81-8bc4-9a543deab17d","slug":"acute-exacerbation-of-asthma","fullItemName":"Scenario: Acute exacerbation of asthma"},{"id":"45a1b06c-1e5d-56b4-8da7-a8abf4f6c7cc","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"fb9dc424-4306-54a1-b06b-1b01273ac473","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"52940123-8084-55c3-b593-cc9fe50daf8f","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"5eb1288c-29af-59c1-b623-bd0010732835","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"dc8f7545-ff7a-5bf1-8ac8-95161137fac5","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"4d715496-c821-52e3-8ea0-d05cfb33d3eb","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"d8174f33-d787-5076-88b5-f4c67df93128","slug":"leukotriene-receptor-antagonists","fullItemName":"Leukotriene receptor antagonists"},{"id":"a556cd4f-1851-52fd-a993-34e977a27fd2","slug":"muscarinic-agents","fullItemName":"Muscarinic agents"},{"id":"0cea3b69-b77b-505e-bded-6fceaca145df","slug":"theophylline","fullItemName":"Theophylline"},{"id":"550429f1-7cab-5f16-b476-e479d8084c03","slug":"cromones","fullItemName":"Cromones"}]},{"id":"76b3dfce-ba54-5456-a259-79b345a5e064","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e31b3681-17cc-5ff2-ba28-d3b1fcb0a82c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2bcf3eeb-fd2e-5d40-a52f-da626afbbe01","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"14ea4312-4846-5381-a82c-dc6b03a60d04","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e4987bc8-0a78-59eb-bfda-f9de7c9ee182","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"be4f3045-8192-53b7-81a3-b460bb2218bc","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"82ae443c-942c-5053-a988-38bce8dec570","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"efdf3cf8-dee5-5351-9d2d-346b4fdf9faf","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"770d55df-2c61-5d1e-83d9-92b12ccae96a","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"6a0a4376-5060-5c48-bd6a-5f27a6c4331f","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field f843999f-44f8-45d7-a399-94891802c30c --><h3>Previous changes</h3><!-- end field f843999f-44f8-45d7-a399-94891802c30c -->","summary":null,"htmlStringContent":"<!-- begin item 81bf6b86-e61e-487d-a644-cea483a74251 --><!-- begin field 94c45a69-5659-48bc-b1d6-7f5a12d7dfff --><p><strong>February 2018 </strong>— minor update. Systematic review from Cochrane library - Anti-IL5 therapies for asthma added to new evidence section. </p><p><strong>October to December 2016 </strong>— reviewed and updated. A literature search was conducted in October 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring. No major changes to the recommendations have been made.</p><p><strong>December 2013</strong> — minor update. A broken link to the Children's Asthma Control Test has been fixed.</p><p><strong>July 2013</strong> — minor update. Links to the DVLA website have been updated.</p><p><strong>June 2013</strong> — minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>May 2013</strong> — minor update. Minor change to the text to improve the clarity managing people awaiting hospital admission.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012</strong> — minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>March 2012</strong> — minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><strong>February 2012</strong> — minor update. A recommendation to advise people inhaling terbutaline via a turbohaler to rinse their mouth after each use to minimize systemic adverse effects has been added, following an update to the manufacturer's Summary of Product Characteristics. Issued in March 2012.</p><p><strong>November 2011</strong> — minor update. The black triangle has been removed from Serevent Evohaler<sup>®</sup> (salmeterol cfc-free inhaler); prescriptions have been amended to reflect this. Issued in December 2011.</p><p><strong>June 2011</strong> — annual updates from the <em>British guideline on the management of asthma: a national clinical guideline</em> by SIGN/BTS are now included. Issued in June 2011.</p><p><strong>May 2011</strong> — minor update. The 2011/2012 QOF indicators and the 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>April 2011 </strong>— minor update. Pulmicort pMDI inhalers have been removed from this topic as they have been discontinued. Issued in June 2011.</p><p><strong>March 2011</strong> — topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>February 2011</strong> — minor update. The range of dry powder inhaler devices included as prescriptions has been updated. Issued in February 2011.</p><p><strong>December 2010</strong> — minor update. The Flixotide Diskhaler<sup>®</sup> (fluticasone) range has been discontinued. The prescription has been removed. Issued in December 2010.</p><p><strong>October 2010 </strong>— minor update. Information on fitness to drive from the Driver and Vehicle Licensing Agency's guidance for medical practitioners, <em>At a glance guide to the current medical standards of fitness to drive</em> has been added. Issued in November 2010.</p><p><strong>September 2010</strong> — minor update. The Medicines and Healthcare products Regulatory Agency has issues a reminder to prescribers that, for most children, a daily dose of 24 micrograms formoterol is sufficient. Issued in September 2010.</p><p><strong>March 2010</strong> — minor update. All strengths of Beclazone<sup>®</sup> inhalers have been discontinued. Prescriptions removed. For advice regarding switching from CFC beclometasone to CFC-free beclometasone. Issued in March 2010.</p><p><strong>January 2010</strong> — minor update. Ciclesonide (Alvesco<sup>®</sup>) is no longer a black triangle product. Minor addition to text regarding drug interactions with theophylline. Issued in January 2010.</p><p><strong>December 2009</strong> — minor update. Clenil Modulite<sup>®</sup> (beclometasone CFC-free) is no longer a black triangle product. Prescription updated. Issued in December 2009.</p><p><strong>November 2009</strong> — minor update. The <em>Supporting evidence </em>section on Symbicort Smart® has been reworded to make it clear that the data summarized are from a single Cochrane review. Issued in November 2009.</p><p><strong>August 2009</strong> — minor update. The annual updates from the <em>British guideline on the management of asthma: a national clinical guideline</em> by SIGN/BTS are now included. Issued in August 2009.</p><p><strong>May 2009</strong> — updated to include information and prescriptions for budesonide CFC-free pMDI. The Nebuhaler<sup>®</sup> spacer device has been discontinued. The prescription has been replaced with the NebuChamber<sup>®</sup> spacer device. Issued in June 2009.</p><p><strong>April 2009</strong> — minor update. The Quality and Outcomes Framework (QOF) indicators for stopping smoking that relate to asthma have been added to the <em>Goals and outcome measures</em> section. Issued in May 2009.</p><p><strong>February 2009</strong> — minor update. Flixotide<sup>®</sup> 50 microgram diskhaler and all strengths of the Aerobec<sup>®</sup> breath-actuated inhaler have been discontinued. Prescriptions removed. Issued March 2009.</p><p><strong>August 2008</strong> — update to the diagnosis and assessment sections following the publication of the <em>British guideline on the management of asthma: a national clinical guideline</em> by SIGN/BTS. Issued in November 2008.</p><p><strong>March 2008</strong> — minor update to include advice from the Medicines and Healthcare products Regulatory Agency (MHRA) regarding the use of short-acting beta-<sub>2 </sub>agonists in people who have a history of heart disease. Issued in March 2008.</p><p><strong>September to December 2007 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. This CKS topic includes revisions in the 2007 update to the SIGN/BTS British Guideline on the Management of Asthma.</p><p><strong>June 2007</strong> — updated. Nebuhaler<sup>®</sup> discontinued. Prescriptions replaced with Nebuhaler<sup>®</sup> + mask, which continues to be available. Issued in June 2007.</p><p><strong>May 2007</strong> — updated. Becotide<sup>®</sup> and Becloforte<sup>®</sup> discontinued. Prescriptions removed. Issued in May 2007.</p><p><strong>March 2007</strong> — updated. Prescriptions and dosing information for Clenil Modulite<sup>®</sup> (CFC-free beclometasone) and CFC-free formoterol included. Information on spacer device compatibilities also updated. Issued in March 2007.</p><p><strong>July to September 2006</strong> — updated. Validated in December 2006 and issued in January 2007.</p><p><strong>July 2006 </strong>— minor update. All strengths of Ventodisks<sup>®</sup> (salbutamol dry powder Diskhaler<sup>®</sup>) will be discontinued from the end of September 2006 and prescriptions have been removed. Issued in July 2006.</p><p><strong>April 2006 </strong>— minor update. Prescriptions for CFC-free nedocromil and salmeterol pressurized metered dose inhalers have replaced those for CFC-containing inhalers. Information on changing to CFC-free inhalers included in Medicines Management. Issued in May 2006.</p><p><strong>January 2006</strong> — minor update. Volumatic<sup>®</sup> spacer device re-introduced and prescriptions included; terbutaline pressurized metered dose inhalers have been discontinued and prescriptions removed. Issued in February 2006.</p><p><strong>August 2005</strong> — updated to include revisions in the 2005 update to the SIGN/BTS British Guideline on the Management of Asthma, and the new CMO recommendations on the pneumococcal immunization programme. Volumatic<sup>®</sup> spacer device discontinued and prescriptions removed; advice for using alternative spacer devices included. Validated in September 2005 and issued in November 2005.</p><p><strong>August 2004 </strong>— updated to include revisions in the 2004 update to the SIGN/BTS British Guideline on the Management of Asthma. Validated in September 2004 and issued in November 2004.</p><p><strong>April 2003</strong> — reviewed. Validated in September 2003 and issued in October 2003. This guidance supersedes the CKS guidance <em>Asthma — age under 5 years</em>, which has been withdrawn.</p><p><strong>April 2002</strong> — reviewed and updated to incorporate <em>Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)</em>, technology appraisal guidance no. 38, issued by the National Institute for Health and Care Excellence (April 2002).</p><p><strong>April 1999</strong> — reviewed. Validated in July 1999 and issued in August 1999.</p><p><strong>June 1998</strong> — written.</p><!-- end field 94c45a69-5659-48bc-b1d6-7f5a12d7dfff --><!-- end item 81bf6b86-e61e-487d-a644-cea483a74251 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}